ANI Pharmaceuticals (NASDAQ:ANIP) Director Thomas Haughey Sells 2,000 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey sold 2,000 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director directly owned 38,878 shares of the company’s stock, valued at $3,144,452.64. The trade was a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $81.85 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The stock has a market capitalization of $1.86 billion, a P/E ratio of 20.72 and a beta of 0.44. The company has a 50 day moving average price of $79.51 and a 200 day moving average price of $79.39. ANI Pharmaceuticals, Inc. has a fifty-two week low of $61.17 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter last year, the company posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth $32,992,000. Balyasny Asset Management L.P. raised its stake in ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after acquiring an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth $21,454,000. Rubric Capital Management LP raised its stake in ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after acquiring an additional 200,998 shares in the last quarter. Finally, UBS Group AG raised its stake in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after acquiring an additional 185,172 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on ANIP shares. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.